| Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value |
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value. |
globenewswire.com |
2025-05-08 12:30:00 |
Czytaj oryginał (ang.) |
| Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update |
VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025 $55.6 million private placement completed in December 2024 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2024, and provided a business update. |
globenewswire.com |
2025-03-20 18:05:00 |
Czytaj oryginał (ang.) |
| Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials |
Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinical trials Despite the increased time required to obtain informed consent, 100% of those surveyed continue to offer patients these innovative investigational treatment options CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented novel research evaluating the patient experience and barriers to enrollment and participation in cell and gene therapy (CGT) trials. |
globenewswire.com |
2025-02-13 10:00:00 |
Czytaj oryginał (ang.) |
| Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference |
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference. |
globenewswire.com |
2025-02-03 10:00:00 |
Czytaj oryginał (ang.) |
| Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross |
Vor Biopharma Inc. (VOR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VOR's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross. |
zacks.com |
2025-01-27 12:56:12 |
Czytaj oryginał (ang.) |
| Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors |
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio's Board of Directors, which has been created in connection with the recent private investment in public equity financing (PIPE) which was led by Reid Hoffman. Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Hoffman's investment fund. |
globenewswire.com |
2025-01-08 11:00:00 |
Czytaj oryginał (ang.) |
| Vor Bio Announces $55.6 Million Private Placement |
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33 ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025 |
globenewswire.com |
2024-12-27 11:00:00 |
Czytaj oryginał (ang.) |
| Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design |
CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data, which was presented in a poster at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 8th, demonstrated durable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of improved relapse free survival compared to published high-risk AML comparators. |
globenewswire.com |
2024-12-09 09:30:00 |
Czytaj oryginał (ang.) |
| Vor Bio price target lowered to $8 from $10 at Oppenheimer |
Oppenheimer analyst Matthew Biegler lowered the firm's price target on Vor Bio to $8 from $10 and keeps an Outperform rating on the shares following the Q3 report. The firm cites updated spending estimates based on guidance from management for the target. It acknowledges Vor's "financial overhang," but still views the company as a "deeply discounted innovator in the biotech sector." |
https://thefly.com |
2024-11-08 16:27:27 |
Czytaj oryginał (ang.) |
| Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer |
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company's President and Chief Executive Officer, Dr. Robert Ang. |
globenewswire.com |
2024-09-30 11:00:00 |
Czytaj oryginał (ang.) |
| What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday? |
Thursday, Vor Biopharma Inc. VOR announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by Mylotarg. |
benzinga.com |
2024-09-06 13:35:08 |
Czytaj oryginał (ang.) |
| New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies |
CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit. |
globenewswire.com |
2024-09-05 20:01:00 |
Czytaj oryginał (ang.) |
| Vor Bio to Participate in Upcoming Investor Conferences |
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-08-28 12:00:00 |
Czytaj oryginał (ang.) |
| Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update |
CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2024, and provided a corporate update. |
globenewswire.com |
2024-08-08 20:05:00 |
Czytaj oryginał (ang.) |
| Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 31, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 1,250 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,875 shares of Vor Bio's common stock to one newly hired employee. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”). |
globenewswire.com |
2024-08-02 20:01:00 |
Czytaj oryginał (ang.) |
| Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 3,000 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 4,500 shares of Vor Bio's common stock to three newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”). |
globenewswire.com |
2024-07-09 20:01:00 |
Czytaj oryginał (ang.) |
| Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of June 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 1,000 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,500 shares of Vor Bio's common stock to one newly hired employee. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”). |
globenewswire.com |
2024-06-04 20:01:00 |
Czytaj oryginał (ang.) |
| Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update |
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2024, and provided a business update. |
globenewswire.com |
2024-05-09 20:05:00 |
Czytaj oryginał (ang.) |
| Vor Bio to Participate in Upcoming Investor Conferences |
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-05-06 12:00:00 |
Czytaj oryginał (ang.) |
| Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of May 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 31,750 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 47,625 shares of Vor Bio's common stock to six newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”). |
globenewswire.com |
2024-05-03 20:01:00 |
Czytaj oryginał (ang.) |
| Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors |
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines, bringing a wealth of industry experience and expertise to Vor Bio's Board. |
globenewswire.com |
2024-05-02 20:01:00 |
Czytaj oryginał (ang.) |
| Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock |
Vor Biopharma (VOR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. |
zacks.com |
2024-04-04 13:36:05 |
Czytaj oryginał (ang.) |
| Vor Bio to Participate in Upcoming Investor Conferences |
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-04-01 12:00:00 |
Czytaj oryginał (ang.) |
| The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness |
In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return. |
investorplace.com |
2024-03-28 16:28:50 |
Czytaj oryginał (ang.) |
| Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update |
CAMBRIDGE, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2023, and provided a business update. |
globenewswire.com |
2024-03-20 18:05:00 |
Czytaj oryginał (ang.) |
| Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of March 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 4,250 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 6,375 shares of Vor Bio's common stock to two newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”). |
globenewswire.com |
2024-03-05 18:01:00 |
Czytaj oryginał (ang.) |